STOCK MARKET REPORT by GRIMALDI & PARTNERS

MONTH REVIEW - AUGUST 2021

The international stock markets ended August with gains.

DRIVING FACTORS:

In general, the prospect of an unchanged, very loose monetary policy to support the economy continues to ensure positive sentiment on the stock market.
Mostly positive company figures.
The corona worries that have flared up again and again recently and the fear of a sharp rise in prices have recently moved into the background.

Particularly noticeable at TITLE LEVEL:

NOVARTIS reports further positive data on the cholesterol drug Leqvio

The pharmaceutical company Novartis was able to confirm the effectiveness of the drug with new study data on its cholesterol-lowering drug Leqvio (Inclisiran). Treated were patients with atherosclerotic cardiovascular diseases.

The data come from separate post-hoc analyzes of phase III studies. In patients with atherosclerotic cardiovascular disease (ASCVD) with established cerebrovascular disease (CeVD) and polyvascular disease (PVD), a sustainable reduction in "low-density lipoprotein cholesterol" (LDL-C) has been demonstrated.

According to Novartis, Leqvio is the first and only approved LDL-C lowering treatment with a small interfering RNA (siRNA) in Europe. In addition, approval in the USA is currently being examined.

SIKA takes over Chinese manufacturer of roof systems

The construction supplier Sika buys in China. With the Shenzhen Landun Holding, a manufacturer of products and technologies for the sealing of buildings joins the people of Central Switzerland.

Landun employs more than 200 people and operates two production facilities. Different foils and coatings for different applications are produced there. Sika does not name a purchase price.

Analysts are fundamentally positive about the takeover.

MONTH OUTLOOK

(...)

STOCK RECOMMENDATION

(...)

You can order the full version of our stock market blog or subscribe. Simply send us your request by email to info@grimaldi-partners.ch

Thank you for your interest!